



## Clinical trial results:

### A Study to Assess the Pharmacokinetics and the Ability for Pediatric Patients with Type 2 Diabetes to Swallow MK-0431A XR Tablets

#### Summary

EudraCT number	2020-003731-22
Trial protocol	Outside EU/EEA
Global end of trial date	29 April 2014

#### Results information

Result version number	v1 (current)
This version publication date	04 October 2020
First version publication date	04 October 2020

#### Trial information

##### Trial identification

Sponsor protocol code	0431A-296
-----------------------	-----------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01557504
WHO universal trial number (UTN)	-
Other trial identifiers	Merck Protocol Number: MK-0431A-296

Notes:

#### Sponsors

Sponsor organisation name	Merck Sharp & Dohme Corp.
Sponsor organisation address	2000 Galloping Hill Road, Kenilworth, NJ, United States, 07033
Public contact	Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com
Scientific contact	Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	29 April 2014
Is this the analysis of the primary completion data?	Yes
Primary completion date	29 April 2014
Global end of trial reached?	Yes
Global end of trial date	29 April 2014
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The purpose of this study is to assess:

- (1) The safety and tolerability of two sitagliptin 50 mg/metformin 1000 mg XR tablets in pediatric participants with type 2 diabetes mellitus (T2DM), aged 10 to 17 years
- (2) The ability of pediatric participants with T2DM, aged 10 to 17 years, to swallow two sitagliptin 50 mg/metformin 1000 mg XR tablets or two matching placebo tablets (excluding marking)
- (3) The pharmacokinetics of sitagliptin and metformin following the administration of two sitagliptin 50 mg/metformin 1000 mg XR tablets to pediatric participants with T2DM, aged 10 to 17 years.

Protection of trial subjects:

This study was conducted in conformance with Good Clinical Practice standards and applicable country and/or local statutes and regulations regarding ethical committee review, informed consent, and the protection of human subjects participating in biomedical research.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	02 August 2012
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	United States: 25
Worldwide total number of subjects	25
EEA total number of subjects	0

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	1
Adolescents (12-17 years)	24
Adults (18-64 years)	0

From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Participant is a male or female, between 10 and 17 years of age.

### Pre-assignment

Screening details:

1. Female participants of reproductive potential must demonstrate a nongravid state.
2. Participants must have:
  - Type 2 diabetes (T2D) diagnosed by American Diabetes Association (ADA) criteria.
  - No clinically significant abnormality on electrocardiogram (ECG).
  - No clinical or laboratory evidence of type 1 diabetes.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Sitagliptin/Metformin XR Followed by Placebo

Arm description:

Day 1 (Period 1): participants received a single dose of two sitagliptin/metformin XR tablets with a low-to moderate-fat meal (breakfast). Days 2-4 (Period 1): participants received a single dose of two matching placebo tablets. Days 5-9 (Period 2): participants received a single dose of two matching placebo tablets with the evening meal.

Arm type	Experimental
Investigational medicinal product name	Sitagliptin/Metformin XR
Investigational medicinal product code	
Other name	MK-0431A XR
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Sitagliptin phosphate 50mg/Metformin hydrochloride 1000mg

Investigational medicinal product name	Placebo for Sitagliptin/Metformin XR
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

0mg/0mg

Investigational medicinal product name	Thyroid Hormone
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Concomitant use of thyroid hormone (TH) will also be permitted during the study provided the participant has been receiving a stable dose for at least 12 weeks prior to study drug administration and is euthyroid as documented by thyroid-stimulation hormone (TSH) testing at prestudy. TH should also be held prior to study drug administration and for 24 hours postdose. TH administration can be re-initiated following completion of the 24-hour procedures.

Investigational medicinal product name	Metformin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

**Dosage and administration details:**

Concomitant use of metformin will be permitted during the study provided the participant has been receiving a stable metformin dose for at least 12 weeks prior to the dose of study drug. Metformin should be held prior to study drug administration and for 24 hours postdose. Metformin administration can be re-initiated following completion of the 24-hour postdose procedures.

<b>Arm title</b>	Placebo
------------------	---------

**Arm description:**

Days 1-4 (Period 1): participants received a single dose of two matching placebo tablets. Days 5-9 (Period 2): participants received a single dose of two matching placebo tablets with the evening meal.

Arm type	Placebo
Investigational medicinal product name	Placebo for Sitagliptin/Metformin XR
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

**Dosage and administration details:**

0mg/0mg

Investigational medicinal product name	Metformin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

**Dosage and administration details:**

Concomitant use of metformin will be permitted during the study provided the participant has been receiving a stable metformin dose for at least 12 weeks prior to the dose of study drug. Metformin should be held prior to study drug administration and for 24 hours postdose. Metformin administration can be re-initiated following completion of the 24-hour postdose procedures.

Investigational medicinal product name	Thyroid Hormone
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

**Dosage and administration details:**

Concomitant use of thyroid hormone (TH) will also be permitted during the study provided the participant has been receiving a stable dose for at least 12 weeks prior to study drug administration and is euthyroid as documented by thyroid-stimulation hormone (TSH) testing at prestudy. TH should also be held prior to study drug administration and for 24 hours postdose. TH administration can be re-initiated following completion of the 24-hour procedures.

<b>Number of subjects in period 1</b>	Sitagliptin/Metformin XR Followed by Placebo	Placebo
Started	13	12
Completed	12	12
Not completed	1	0
Physician decision	1	-



## Baseline characteristics

### Reporting groups

Reporting group title	Sitagliptin/Metformin XR Followed by Placebo
Reporting group description:	
Day 1 (Period 1): participants received a single dose of two sitagliptin/metformin XR tablets with a low-to moderate-fat meal (breakfast). Days 2-4 (Period 1): participants received a single dose of two matching placebo tablets. Days 5-9 (Period 2): participants received a single dose of two matching placebo tablets with the evening meal.	
Reporting group title	Placebo
Reporting group description:	
Days 1-4 (Period 1): participants received a single dose of two matching placebo tablets. Days 5-9 (Period 2): participants received a single dose of two matching placebo tablets with the evening meal.	

Reporting group values	Sitagliptin/Metformin XR Followed by Placebo	Placebo	Total
Number of subjects	13	12	25
Age Categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	1	1
Adolescents (12-17 years)	13	11	24
Adults (18-64 years)	0	0	0
From 65-84 years	0	0	0
85 years and over	0	0	0
Age Continuous Units: years			
arithmetic mean	14.7	14.8	-
standard deviation	± 1.8	± 2.0	-
Gender Categorical Units: Subjects			
Female	9	8	17
Male	4	4	8

## End points

### End points reporting groups

Reporting group title	Sitagliptin/Metformin XR Followed by Placebo
Reporting group description: Day 1 (Period 1): participants received a single dose of two sitagliptin/metformin XR tablets with a low-to moderate-fat meal (breakfast). Days 2-4 (Period 1): participants received a single dose of two matching placebo tablets. Days 5-9 (Period 2): participants received a single dose of two matching placebo tablets with the evening meal.	
Reporting group title	Placebo
Reporting group description: Days 1-4 (Period 1): participants received a single dose of two matching placebo tablets. Days 5-9 (Period 2): participants received a single dose of two matching placebo tablets with the evening meal.	
Subject analysis set title	All Treated Participants
Subject analysis set type	Per protocol
Subject analysis set description: All participants who completed at least one period of treatment and had available data.	
Subject analysis set title	Sitagliptin
Subject analysis set type	Per protocol
Subject analysis set description: Day 1 (Period 1): participants received a single dose of two sitagliptin/metformin XR tablets with a low-to moderate-fat meal (breakfast). Days 2-4 (Period 1): participants received a single dose of two matching placebo tablets. Days 5-9 (Period 2): participants received a single dose of two matching placebo tablets with the evening meal.	
Subject analysis set title	Metformin
Subject analysis set type	Per protocol
Subject analysis set description: Day 1 (Period 1): participants received a single dose of two sitagliptin/metformin XR tablets with a low-to moderate-fat meal (breakfast). Days 2-4 (Period 1): participants received a single dose of two matching placebo tablets. Days 5-9 (Period 2): participants received a single dose of two matching placebo tablets with the evening meal.	

### Primary: Number of Participants Who Successfully Swallowed Study Medication (Med) on Day 2

End point title	Number of Participants Who Successfully Swallowed Study Medication (Med) on Day 2 <sup>[1]</sup>
End point description: The Swallowing Ability Questionnaire was completed on Day 2 after the participant received two matching placebo tablets (excluding marking) following consumption of a low-to-moderate-fat meal in pediatric participants aged 10 to 17 years. The questionnaire consisted of 5 parts: 1. Could only swallow study med with help; 2. Easy to start swallowing study med; 3. Easy to swallow study med; 4. Felt like study med got stuck in throat, and 5. Had to swallow study med more than once. The number of participants who strongly agreed or agreed in each of the 5 parts is reported. Per protocol population defined as all participants who completed at least one period of treatment and had available data. On Day 2, all participants received matching placebo, so the two treatment groups were pooled on Day 2.	
End point type	Primary
End point timeframe: Day 2	
Notes: [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No statistical analysis was planned or performed for this endpoint.	



End point values	All Treated Participants			
Subject group type	Subject analysis set			
Number of subjects analysed	24			
Units: Participants				
Strongly Agreed: 1. Could Swallow Med With Help	6			
Agreed: 1. Could Only Swallow Med With Help	7			
Strongly Agreed: 2. Easy to Start Swallowing Med	10			
Agreed: 2. Easy to Start Swallowing Med	12			
Strongly Agreed: 3. Easy to Swallow Med	13			
Agreed: 3. Easy to Swallow Med	10			
Strongly Agreed: 4. Felt Like Med Stuck in Throat	0			
Agreed: 4. Felt Like Med Got Stuck in Throat	4			
Strongly Agreed: 5. Had to Swallow Med >1	2			
Agreed: 5. Had to Swallow Med >1	3			

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of Participants Who Successfully Swallowed Study Med on Day 4

End point title	Number of Participants Who Successfully Swallowed Study Med on Day 4 <sup>[2]</sup>
-----------------	---

End point description:

The Swallowing Ability Questionnaire was completed on Day 4 after the participant received two matching placebo tablets (excluding marking) following consumption of a low- to moderate-fat meal in pediatric participants aged 10 to 17 years. The questionnaire consisted of 5 parts: 1. Could only swallow study med with help; 2. Easy to start swallowing study med; 3. Easy to swallow study med; 4. Felt like study med got stuck in throat, and 5. Had to swallow study med more than once. The number of participants who strongly agreed or agreed in each of the 5 parts is reported. Per protocol population defined as all participants who completed at least one period of treatment and had available data. On Day 4, all participants received matching placebo, so the two treatment groups were pooled on Day 4.

End point type	Primary
----------------	---------

End point timeframe:

Day 4

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was planned or performed for this endpoint.

End point values	All Treated Participants			
Subject group type	Subject analysis set			
Number of subjects analysed	24			
Units: Participants				
Strongly Agreed: 1. Could Swallow Med With Help	6			

Agreed: 1. Could Only Swallow Med With Help	6			
Strongly Agreed: 2. Easy to Start Swallowing Med	8			
Agreed: 2. Easy to Start Swallowing Med	14			
Strongly Agreed: 3. Easy to Swallow Med	8			
Agreed: 3. Easy to Swallow Med	15			
Strongly Agreed: 4. Felt Like Med Stuck in Throat	0			
Agreed: 4. Felt Like Med Got Stuck in Throat	4			
Strongly Agreed: 5. Had to Swallow Med >1	0			
Agreed: 5. Had to Swallow Med >1	5			

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of Participants Who Successfully Swallowed Study Med on Day 6

End point title	Number of Participants Who Successfully Swallowed Study Med on Day 6 <sup>[3]</sup>
-----------------	---

End point description:

The Swallowing Ability Questionnaire was completed on Day 6 after the participant received two matching placebo tablets (excluding marking) following consumption of a low- to moderate-fat meal in pediatric participants aged 10 to 17 years. The questionnaire consisted of 5 parts: 1. Could only swallow study med with help; 2. Easy to start swallowing study med; 3. Easy to swallow study med; 4. Felt like study med got stuck in throat, and 5. Had to swallow study med more than once. The number of participants who strongly agreed or agreed in each of the 5 parts is reported. Per protocol population defined as all participants who completed at least one period of treatment and had available data. On Day 6, all participants received matching placebo, so the two treatment groups were pooled on Day 6.

End point type	Primary
----------------	---------

End point timeframe:

Day 6

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was planned or performed for this endpoint.

End point values	All Treated Participants			
Subject group type	Subject analysis set			
Number of subjects analysed	24			
Units: Participants				
Strongly Agreed: 1. Could Swallow Med With Help	5			
Agreed: 1. Could Only Swallow Med With Help	7			
Strongly Agreed: 2. Easy to Start Swallowing Med	10			
Agreed: 2. Easy to Start Swallowing Med	11			
Strongly Agreed: 3. Easy to Swallow Med	11			

Agreed: 3. Easy to Swallow Med	12			
Strongly Agreed: 4. Felt Like Med Stuck in Throat	0			
Agreed: 4. Felt Like Med Got Stuck in Throat	3			
Strongly Agreed: 5. Had to Swallow Med >1	2			
Agreed: 5. Had to Swallow Med >1	5			

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of Participants Who Successfully Swallowed Study Med on Day 9

End point title	Number of Participants Who Successfully Swallowed Study Med on Day 9 <sup>[4]</sup>
-----------------	---

End point description:

The Swallowing Ability Questionnaire was completed on Day 9 after the participant received two matching placebo tablets (excluding marking) following consumption of a low- to moderate-fat meal in pediatric participants aged 10 to 17 years. The questionnaire consisted of 5 parts: 1. Could only swallow study med with help; 2. Easy to start swallowing study med; 3. Easy to swallow study med; 4. Felt like study med got stuck in throat, and 5. Had to swallow study med more than once. The number of participants who strongly agreed or agreed in each of the 5 parts is reported. Per protocol population defined as all participants who completed at least one period of treatment and had available data. On Day 9, all participants received matching placebo, so the two treatment groups were pooled on Day 9.

End point type	Primary
----------------	---------

End point timeframe:

Day 9

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was planned or performed for this endpoint.

End point values	All Treated Participants			
Subject group type	Subject analysis set			
Number of subjects analysed	24			
Units: Participants				
Strongly Agreed: 1. Could Swallow Med With Help	9			
Agreed: 1. Could Only Swallow Med With Help	5			
Strongly Agreed: 2. Easy to Start Swallowing Med	9			
Agreed: 2. Easy to Start Swallowing Med	13			
Strongly Agreed: 3. Easy to Swallow Med	12			
Agreed: 3. Easy to Swallow Med	11			
Strongly Agreed: 4. Felt Like Med Stuck in Throat	1			
Agreed: 4. Felt Like Med Got Stuck in Throat	1			
Strongly Agreed: 5. Had to Swallow Med >1	2			
Agreed: 5. Had to Swallow Med >1	5			

## Statistical analyses

No statistical analyses for this end point

### Primary: Area Under the Curve 0 to Last (AUC 0-last) of Sitagliptin Following Single Administration of Sitagliptin/Metformin XR

End point title	Area Under the Curve 0 to Last (AUC 0-last) of Sitagliptin Following Single Administration of Sitagliptin/Metformin XR <sup>[5]</sup> <sup>[6]</sup>
-----------------	--

End point description:

AUC0-last is a measure of the total amount of drug in the plasma from the dose to the last measurable sample at which the concentration is at or above lower limit of quantification (LLQ). In this study, metformin products were withheld 24 hours (hrs.) prior to sitagliptin/metformin XR administration and were permitted to re-initiate 24 hrs. post study drug administration. Owing to resumption of therapeutic metformin administration 24 hrs. after sitagliptin/metformin XR administration for all participants, metformin pharmacokinetic analyses were restricted to maximum plasma concentration (C<sub>max</sub>), time to maximum plasma concentration (T<sub>max</sub>) and area under the curve 0 to 24 hrs. (AUC0-24hr). Therefore, metformin arm is not included in this endpoint. Per protocol population defined as all participants who completed at least one period of treatment (Sitagliptin/Metformin XR Followed by Placebo arm) and had available data.

End point type	Primary
----------------	---------

End point timeframe:

Pre-dose, and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, and 72 hours post-dose

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was planned or performed for this endpoint.

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No statistical analysis was planned or performed for this endpoint.

End point values	Sitagliptin/Metformin XR Followed by Placebo			
Subject group type	Reporting group			
Number of subjects analysed	12			
Units: nM*hr				
geometric mean (geometric coefficient of variation)	5940 (± 25.7)			

## Statistical analyses

No statistical analyses for this end point

### Primary: AUC 0-24 of Sitagliptin Following Single Administration of Sitagliptin/Metformin XR

End point title	AUC 0-24 of Sitagliptin Following Single Administration of Sitagliptin/Metformin XR <sup>[7]</sup> <sup>[8]</sup>
-----------------	---

End point description:

AUC0-24 is a measure of the total amount of drug in the plasma from the dose to 24 hours after the dose. Due different units of measure for sitagliptin and metformin, metformin data are presented in another endpoint. Per protocol population defined as all participants who completed at least one period of treatment (Sitagliptin/Metformin XR Followed by Placebo arm) and had available data.

End point type	Primary
----------------	---------

End point timeframe:

Pre-dose, and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, and 24 hours post-dose

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was planned or performed for this endpoint.

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No statistical analysis was planned or performed for this endpoint.

<b>End point values</b>	Sitagliptin/Metformin XR Followed by Placebo			
Subject group type	Reporting group			
Number of subjects analysed	12			
Units: nM*hr				
geometric mean (geometric coefficient of variation)	5310 ( $\pm$ 22.4)			

## Statistical analyses

No statistical analyses for this end point

## Primary: AUC 0-24 of Metformin Following Single Administration of Sitagliptin/Metformin XR

End point title	AUC 0-24 of Metformin Following Single Administration of Sitagliptin/Metformin XR <sup>[9][10]</sup>
-----------------	--

End point description:

AUC0-24 is a measure of the total amount of drug in the plasma from the dose to 24 hours after the dose. In this study, metformin products were withheld 24 hours prior to sitagliptin/metformin XR administration and were permitted to re-initiate 24 hours post study drug administration. Due different units of measure for sitagliptin and metformin, sitagliptin data are presented in another endpoint. Per protocol population defined as all participants who completed at least one period of treatment (Sitagliptin/Metformin XR Followed by Placebo arm) and had available data.

End point type	Primary
----------------	---------

End point timeframe:

Pre-dose, and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, and 24 hours post-dose

Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was planned or performed for this endpoint.

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No statistical analysis was planned or performed for this endpoint.

<b>End point values</b>	Sitagliptin/Metformin XR Followed by Placebo			
Subject group type	Reporting group			
Number of subjects analysed	12			
Units: ng*hr/mL				
geometric mean (geometric coefficient of variation)	14200 ( $\pm$ 39.7)			

## Statistical analyses

No statistical analyses for this end point

## Primary: Area Under the Curve 0 to Infinity (AUC 0- $\infty$ ) of Sitagliptin Following Single Administration of Sitagliptin/Metformin XR

End point title	Area Under the Curve 0 to Infinity (AUC 0- $\infty$ ) of Sitagliptin Following Single Administration of Sitagliptin/Metformin XR <sup>[11][12]</sup>
-----------------	--

End point description:

AUC0- $\infty$  is a measure of the mean concentration levels of drug in the plasma after the dose. In this study, metformin products were withheld 24 hours prior to sitagliptin/metformin XR administration and were permitted to re-initiate 24 hours post study drug administration. Owing to resumption of therapeutic metformin administration 24 hours after sitagliptin/metformin XR administration for all participants, metformin pharmacokinetic analyses were restricted to C<sub>max</sub>, T<sub>max</sub> and AUC0-24hr. Therefore, metformin arm is not included in this endpoint. Per protocol population defined as all participants who completed at least one period of treatment (Sitagliptin/Metformin XR Followed by Placebo arm) and had available data.

End point type	Primary
----------------	---------

End point timeframe:

Pre-dose, and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, and 72 hours post-dose

Notes:

[11] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was planned or performed for this endpoint.

[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No statistical analysis was planned or performed for this endpoint.

<b>End point values</b>	Sitagliptin/Metformin XR Followed by Placebo			
Subject group type	Reporting group			
Number of subjects analysed	12			
Units: nM*hr				
geometric mean (geometric coefficient of variation)	6020 ( $\pm$ 24.8)			

## Statistical analyses

No statistical analyses for this end point

### Primary: Cmax of Sitagliptin Following Single Dose Administration of Sitagliptin/Metformin XR

End point title	Cmax of Sitagliptin Following Single Dose Administration of Sitagliptin/Metformin XR <sup>[13]</sup> <sup>[14]</sup>
-----------------	--

End point description:

Cmax is a measure of the maximum amount of drug in the plasma after the dose is given. Due different units of measure for sitagliptin and metformin, metformin data are presented in another endpoint. Per protocol population defined as all participants who completed at least one period of treatment (Sitagliptin/Metformin XR Followed by Placebo arm) and had available data.

End point type	Primary
----------------	---------

End point timeframe:

Pre-dose, and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, and 72 hours post-dose

Notes:

[13] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was planned or performed for this endpoint.

[14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No statistical analysis was planned or performed for this endpoint.

End point values	Sitagliptin/Metformin XR Followed by Placebo			
Subject group type	Reporting group			
Number of subjects analysed	12			
Units: nM				
geometric mean (geometric coefficient of variation)	757 (± 40.1)			

### Statistical analyses

No statistical analyses for this end point

### Primary: Cmax of Metformin Following Single Dose Administration of Sitagliptin/Metformin XR

End point title	Cmax of Metformin Following Single Dose Administration of Sitagliptin/Metformin XR <sup>[15]</sup> <sup>[16]</sup>
-----------------	--

End point description:

Cmax is a measure of the maximum amount of drug in the plasma after the dose is given. Due different units of measure for sitagliptin and metformin, sitagliptin data are presented in another endpoint. In this study, metformin products were withheld 24 hours prior to sitagliptin/metformin XR administration and were permitted to re-initiate 24 hours post study drug administration. Per protocol population defined as all participants who completed at least one period of treatment (Sitagliptin/Metformin XR Followed by Placebo arm) and had available data.

End point type	Primary
----------------	---------

End point timeframe:

Pre-dose, and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, and 72 hours post-dose

Notes:

[15] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was planned or performed for this endpoint.

[16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No statistical analysis was planned or performed for this endpoint.

<b>End point values</b>	Sitagliptin/Metformin XR Followed by Placebo			
Subject group type	Reporting group			
Number of subjects analysed	12			
Units: ng/mL				
geometric mean (geometric coefficient of variation)	1490 ( $\pm$ 29.1)			

## Statistical analyses

No statistical analyses for this end point

## Primary: Tmax of Sitagliptin and Metformin Following Single Dose Administration of Sitagliptin/Metformin XR

End point title	Tmax of Sitagliptin and Metformin Following Single Dose Administration of Sitagliptin/Metformin XR <sup>[17]</sup>
-----------------	--

End point description:

Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose. In this study, metformin products were withheld 24 hours prior to sitagliptin/metformin XR administration and were permitted to re-initiate 24 hours post study drug administration. Per protocol population defined as all participants who completed at least one period of treatment (Sitagliptin/Metformin XR followed by placebo arm) and had available data.

End point type	Primary
----------------	---------

End point timeframe:

Pre-dose, and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, and 72 hours post-dose

Notes:

[17] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was planned or performed for this endpoint.

<b>End point values</b>	Sitagliptin	Metformin		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	12	12		
Units: Hour				
median (full range (min-max))	1.52 (0.97 to 3.05)	5.00 (3.98 to 7.22)		

## Statistical analyses



No statistical analyses for this end point

### Primary: Apparent Terminal Half Life (t<sub>1/2</sub>) of Sitagliptin Following Single Dose Administration of Sitagliptin/Metformin XR

End point title	Apparent Terminal Half Life (t <sub>1/2</sub> ) of Sitagliptin Following Single Dose Administration of Sitagliptin/Metformin XR <sup>[18]</sup>
-----------------	---

End point description:

Apparent terminal half-life is the time required to divide the plasma (serum) concentration of drug by two after reaching pseudo-equilibrium. (Note: it is not the time required to eliminate half the administered dose.) In this study, metformin products were withheld 24 hours prior to sitagliptin/metformin XR administration and were permitted to re-initiate 24 hours post study drug administration. Owing to resumption of therapeutic metformin administration 24 hours after sitagliptin/metformin XR administration for all participants, metformin pharmacokinetic analyses were restricted to C<sub>max</sub>, T<sub>max</sub>, and AUC<sub>0-24hr</sub>. Therefore, metformin arm is not included in this endpoint. Per protocol population defined as all participants who completed at least one period of treatment (Sitagliptin/Metformin XR Followed by Placebo arm) and had available data.

End point type	Primary
----------------	---------

End point timeframe:

Pre-dose, and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, and 72 hours post-dose

Notes:

[18] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was planned or performed for this endpoint.

End point values	Sitagliptin			
Subject group type	Subject analysis set			
Number of subjects analysed	12			
Units: Hour				
geometric mean (geometric coefficient of variation)	10.0 (± 27.3)			

### Statistical analyses

No statistical analyses for this end point

### Primary: Number of Participants Who Experienced an Adverse Event (AE)

End point title	Number of Participants Who Experienced an Adverse Event (AE) <sup>[19]</sup>
-----------------	--

End point description:

An AE was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an Investigational Medicinal Product (IMP), regardless of causal relationship and even if no IMP has been administered. The analysis population included all participants who received at least one dose of study drug.

End point type	Primary
----------------	---------

End point timeframe:

Up to 23 days (including approximately 10 to 14 days after the last dose of study drug)

Notes:

[19] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was planned or performed for this endpoint.

End point values	Sitagliptin/Metformin XR Followed by Placebo	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	13	12		
Units: Participants	5	5		

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of Participants Who Experienced an Abnormal Vital Sign Value

End point title	Number of Participants Who Experienced an Abnormal Vital Sign Value <sup>[20]</sup>
-----------------	---

End point description:

Vital sign measurements included blood pressure, heart rate, respiratory rate, and oral temperature. The analysis population included all participants who received at least one dose of study drug.

End point type	Primary
----------------	---------

End point timeframe:

Up to 23 days (including approximately 10 to 14 days after the last dose of study drug)

Notes:

[20] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was planned or performed for this endpoint.

End point values	Sitagliptin/Metformin XR Followed by Placebo	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	13	12		
Units: Participants	0	0		

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of Participants Who Discontinued Study Drug Due to an AE

End point title	Number of Participants Who Discontinued Study Drug Due to an AE <sup>[21]</sup>
-----------------	---

End point description:

An AE was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an IMP, regardless of causal relationship and even if no IMP has been administered. The analysis population included all participants who received at least one dose of study drug.

End point type	Primary
----------------	---------

End point timeframe:

Up to 9 days

---

Notes:

[21] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was planned or performed for this endpoint.

<b>End point values</b>	Sitagliptin/Metformin XR Followed by Placebo	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	13	12		
Units: Participants	0	0		

### **Statistical analyses**

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Up to 23 days (including approximately 10 to 14 days after the last dose of study drug)

Adverse event reporting additional description:

An AE was any untoward medical occurrence of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens during a clinical study with an Investigational Medicinal Product (IMP), regardless of causal relationship or administration. The analysis population included all participants who received at least one dose of study drug.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	17.0
--------------------	------

### Reporting groups

Reporting group title	Sitagliptin/Metformin XR Followed by Placebo
-----------------------	--

Reporting group description: -

Reporting group title	Placebo
-----------------------	---------

Reporting group description: -

Serious adverse events	Sitagliptin/Metformin XR Followed by Placebo	Placebo	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 13 (0.00%)	0 / 12 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Sitagliptin/Metformin XR Followed by Placebo	Placebo	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	5 / 13 (38.46%)	5 / 12 (41.67%)	
Investigations			
Urine analysis abnormal			
subjects affected / exposed	1 / 13 (7.69%)	0 / 12 (0.00%)	
occurrences (all)	1	0	
Nervous system disorders			
Headache			

subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 12 (0.00%) 0	
Immune system disorders Seasonal allergy subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 12 (0.00%) 0	
Gastrointestinal disorders Diarrhoea subjects affected / exposed occurrences (all)  Vomiting subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1  1 / 13 (7.69%) 1	0 / 12 (0.00%) 0  0 / 12 (0.00%) 0	
Reproductive system and breast disorders Vulvovaginal pruritus subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	1 / 12 (8.33%) 1	
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)  Plantar fasciitis subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0  0 / 13 (0.00%) 0	1 / 12 (8.33%) 1  1 / 12 (8.33%) 1	
Infections and infestations Nasopharyngitis subjects affected / exposed occurrences (all)  Upper respiratory tract infection subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1  0 / 13 (0.00%) 0	1 / 12 (8.33%) 1  1 / 12 (8.33%) 1	
Metabolism and nutrition disorders Hypoglycaemia subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 12 (0.00%) 0	



## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
18 March 2013	Various changes to diet restrictions and requirements, safety laboratory tests, and other blood draws.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported